Incorporation of patients treated with caplacizumab and patients not receiving caplacizumab treatment. We identified 69 patients with iTTP from the thrombotic microangiopathy (TMA) registry. Among those who satisfied the exclusion criteria, 30 acute episodes in 29 patients were included in this study. Among these, 14 received caplacizumab treatment (designated as the caplacizumab group), whereas the remaining 16 did not receive caplacizumab treatment (referred to as the non-caplacizumab group).